Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 6Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1HRD Cancer 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Brain Neoplasms 1

Interventions

sotorasib 1pembrolizumab 1lorlatinib 1liposomal doxorubicin 1encorafenib 1cemiplimab 1binimetinib 1berzosertib 1Topotecan 1Taxes 1Paclitaxel 1PX-866 1NVP-BKM120 1Lomustine 1Irinotecan 1Gemcitabine 1Everolimus 1Doxorubicin 1Docetaxel 1Cetuximab 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × berzosertib × Thoracic × Clear all
NCT04768296 2024-09-26

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

EMD Serono

Phase 2 Completed
76 enrolled 42 charts
Thoracic

Hereditary Sensory and Autonomic Neuropathies, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡